Catalyst Biosciences, Inc. (CBIO) financial statements (2020 and earlier)

Company profile

Business Address 611 GATEWAY BLVD., SUITE 710
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:778594105120129136
Cash and cash equivalents15231725313647
Short-term investments61627780899390
Other undisclosed cash, cash equivalents, and short-term investments0000(0)  
Restricted cash and investments  00000
Receivables15      
Other undisclosed current assets4444443
Total current assets:968998109124133139
Noncurrent Assets
Operating lease, right-of-use asset22  
Property, plant and equipment0000000
Other noncurrent assets0000100
Other undisclosed noncurrent assets  22   
Total noncurrent assets:2333111
TOTAL ASSETS:9992101112125133140
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13964532
Accounts payable4200100
Accrued liabilities7543221
Employee-related liabilities2211111
Deferred revenue15   
Debt00     
Deferred rent credit    000
Other undisclosed current liabilities  00   
Total current liabilities:29964532
Noncurrent Liabilities
Long-term debt and lease obligation11     
Operating lease, liability11  
Liabilities, other than long-term debt    000
Deferred rent credit    000
Other undisclosed noncurrent liabilities  22   
Total noncurrent liabilities:1122000
Total liabilities:301186533
Stockholders' equity
Stockholders' equity attributable to parent688193106120130137
Common stock0000000
Additional paid in capital327326325324323322322
Accumulated other comprehensive income (loss)0000(0)(0)0
Accumulated deficit(259)(245)(232)(218)(203)(193)(185)
Total stockholders' equity:688193106120130137
TOTAL LIABILITIES AND EQUITY:9992101112125133140

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Operating expenses(14)(13)(14)(16)(12)(8)(7)
Operating loss:(14)(13)(14)(16)(12)(8)(7)
Nonoperating income (expense)0   0(0)0
Other nonoperating income (expense)0    (0)0
Loss before gain (loss) on sale of properties:(14)(13)(14)(16)(12)(8)(7)
Other undisclosed net income0  11  
Net loss:(14)(13)(14)(15)(11)(8)(7)
Other undisclosed net income attributable to parent 01  11
Net loss available to common stockholders, diluted:(14)(13)(14)(15)(11)(8)(6)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(14)(13)(14)(15)(11)(8)(7)
Comprehensive loss:(14)(13)(14)(15)(11)(8)(7)
Other undisclosed comprehensive income, net of tax, attributable to parent0010011
Comprehensive loss, net of tax, attributable to parent:(14)(13)(14)(15)(11)(8)(6)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: